ProMIS Neurosciences (PMN) Earnings Date & Reports

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimerâ€™s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA)... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PMN is expected to report earnings to fall 223.58% to -14 cents per share on May 20

ProMIS Neurosciences PMN Stock Earnings Reports

Q1'25

Est.

$-0.15

Q4'24

Beat

by $0.28

Q3'24

Beat

by $0.38

Q2'24

Beat

by $0.01

Q1'24

Beat

by $0.01

The last earnings report on March 31 showed earnings per share of 11 cents, beating the estimate of -15 cents. With 662.00 shares outstanding, the current market capitalization sits at 23.24M.

View a ticker or compare two or three

Compare

PMN